Multi-modal Imaging and Artificial Intelligence Diagnostic System for Multi-level Clinical Application

Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03899623
Collaborator
(none)
3,000
1
20.3
148

Study Details

Study Description

Brief Summary

This study is to build an multi-modal artificial intelligence ophthalmological imaging diagnostic system covering multi-level medical institutions. We are going to evaluate this system in an evidence-based medicine view, taking diabetic retinopathy as an example. And clinical diagnostic criteria will be made based on this multi-modal artificial intelligence imaging diagnostic system. The study is designed as a cross-sectional study involving 1,000 normal individuals, 1,000 diabetes patients without ocular complications, and 1,000 with diabetic ocular complications. Statistical analysis of the diagnostic sensitivity and specificity of the artificial intelligence system will be made, and ROC curve wil be draw.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    3000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Multi-modal Imaging and Artificial Intelligence Diagnostic System for Multi-level Clinical Application
    Actual Study Start Date :
    Apr 23, 2018
    Anticipated Primary Completion Date :
    Dec 31, 2019
    Anticipated Study Completion Date :
    Dec 31, 2019

    Outcome Measures

    Primary Outcome Measures

    1. The diagnostic sensitivity, specificity and ROC curve of the artificial intelligence(AI) system compared with reference standard (ophthalmologist). [It will take 15~20min for each subject to take the exams.]

      Sensitivity: the percentage of diabetic retinopathy(DR) patients who are correctly identified as having the condition by AI. Sensitivity=True positive/(True positive+False negative). Specificity: the percentage of healthy people who are correctly identified as not having the condition by AI. Specificity=True negative /(True negative +False positive). The ROC curve was plotted with true positive rate (sensitivity) as the ordinate and false positive rate (1-specificity) as the abscissa.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Group A(normal individuals): Meet all the items 1 ~ 5 below

    1. No familial or hereditary retinopathy;

    2. No history of ocular trauma and / or history of ocular disease (except for mild to moderate refractive errors and / or age-related cataracts);

    3. No drug use history that may cause side effects of retina (such as chloroquine, hydroxychloroquine, chlorpromazine, rifampin, etc.); 4 binocular diopter ≤ ± 6.00D; No systemic diseases that may affect the retina.

    Group B(diabetes patients without ocular complications): meet any of 1 to 3, and both 4 to 5 items

    1. Diagnosed with type 1 diabetes for more than 5 years;

    2. Diagnosed with type 2 diabetes patients;

    3. Diagnosis of gestational diabetes patients;

    4. Without systemic disease that may affect the retina except for diabetes;

    5. Meet the standards of 1 to 4 items.

    Group C(patients with diabetic ocular complications): meet with any of 1 to 3, and all 4 to 6 items

    1. Diagnosed with type 1 diabetes for more than 5 years;

    2. Diagnosed with type 2 diabetes patients;

    3. Diagnosis of gestational diabetes patients;

    4. Meet the guidelines for diagnosis and treatment of diabetic retinopathy in any stage of diabetic retinopathy and / or diabetic macular edema.

    5. Without systemic disease that may affect the retina except for diabetes;

    6. A group to meet the criteria for 1 to 4 items.

    Exclusion Criteria:
    1. Refractive pathway is turbid, so that fundus image can not be clearly photographed;

    2. With other fundus diseases and / or other diseases that seriously affect the visual function;

    3. Any eye infection, such as conjunctivitis, keratitis, scleritis, endophthalmitis, acute and chronic dacryocystitis, or eye injury;

    4. Serious systemic diseases such as diabetes, hypertension, heart failur,renal failure;

    5. Can not cooperate with the examiner due to mental or other reasons.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zhongshan Opthalmic Center Guangzhou Guangdong China 510000

    Sponsors and Collaborators

    • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Investigators

    • Principal Investigator: Yuan Jin, Professor, Zhongshan Opthalmic Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jin Yuan, Principal Investigator, Zhongshan Ophthalmic Center, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT03899623
    Other Study ID Numbers:
    • 2017KYPJ104
    First Posted:
    Apr 2, 2019
    Last Update Posted:
    Apr 2, 2019
    Last Verified:
    Mar 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jin Yuan, Principal Investigator, Zhongshan Ophthalmic Center, Sun Yat-sen University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 2, 2019